Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAU | P00749 | 1/20 | 0.39 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.36 |
| ▸ | NOS1 | P29475 | 2/20 | 0.35 |
| ▸ | NOS3 | P29474 | 2/20 | 0.35 |
| ▸ | NOS2 | P35228 | 2/20 | 0.35 |
| ▸ | DAO | P14920 | 1/20 | 0.35 |
| ▸ | ABL1 | P00519 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | MET | P08581 | 1/20 | 0.30 |
| ▸ | JAK2 | O60674 | 1/20 | 0.30 |
| ▸ | USP7 | Q93009 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23556108 | 0.84 | DYRK1A (0.37) | PLAUDYRK1ANOS1NOS3NOS2 | |
| SCHEMBL30133415 | 0.79 | PLAU (0.42) | PLAUDYRK1ANOS1NOS3NOS2 | |
| SCHEMBL31410007 | 0.77 | DAO (0.37) | PLAUDAOALDH1A1 | |
| SCHEMBL2223631 | 0.77 | PLAU (0.50) | PLAUDYRK1ANOS1NOS3NOS2 | |
| SCHEMBL3675394 | 0.77 | PLAU (0.41) | PLAUDYRK1ANOS1NOS3NOS2 | |
| SCHEMBL15662633 | 0.77 | DYRK1A (0.38) | DYRK1AABL1MET | |
| SCHEMBL29142223 | 0.77 | DYRK1A (0.38) | DYRK1A | |
| SCHEMBL2222027 | 0.77 | NOS3 (0.38) | NOS1NOS3NOS2DAOUSP7 | |
| Hydrochloric Acid SCHEMBL3156294 | 0.76 | PLAU (0.40) | PLAUDYRK1ANOS1NOS3NOS2 | |
| SCHEMBL34472031 | 0.75 | FYN (0.38) | DYRK1AUSP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140163069-A1 | COMPOSITIONS OF TARGETED DRUG DEVELOPMENT | Errico, Joseph P. (US) | 2014-06-12 | — | — | US | claimed |
| US-8618302-B2 | Methods and compositions of targeted drug development | Errico, Joseph P. (US) | 2013-12-31 | — | — | US | claimed |
| CN-102811723-A | Methods and compositions for targeted drug development | ERRICO JOSEPH P | 2012-12-05 | — | — | CN | claimed |
| EP-2521553-A2 | METHODS AND COMPOSITIONS OF TARGETED DRUG DEVELOPMENT | Errico, Joseph P. (US) | 2012-11-14 | — | — | EP | claimed |
| US-20110301193-A1 | METHODS AND COMPOSITIONS OF TARGETED DRUG DEVELOPMENT | Errico, Joseph P. (US) | 2011-12-08 | — | — | US | claimed |
| WO-2011085126-A2 | METHODS AND COMPOSITIONS OF TARGETED DRUG DEVELOPMENT | ERRICO JOSEPH P | 2011-07-14 | — | — | WO | claimed |
| WO-2019043635-A1 | D-AMINO ACID OXIDASE ACTIVITY INHIBITING COMPOUNDS | RICHTER GEDEON NYRT. (HU) | 2019-03-07 | — | — | WO | disclosed |
| US-9073858-B2 | Methods of targeted drug development | Errico, Joseph P. (US) | 2015-07-07 | — | — | US | disclosed |
| US-9073858-B2 | Methods of targeted drug development | Errico, Joseph P. (US) | 2015-07-07 | — | — | US | disclosed |
| US-9073858-B2 | Methods of targeted drug development | Errico, Joseph P. (US) | 2015-07-07 | — | — | US | disclosed |
| US-20140194439-A1 | METHODS OF TARGETED DRUG DEVELOPMENT | Errico, Joseph P. (US) | 2014-07-10 | — | — | US | disclosed |
| US-20140194439-A1 | METHODS OF TARGETED DRUG DEVELOPMENT | Errico, Joseph P. (US) | 2014-07-10 | — | — | US | disclosed |
| US-20140194439-A1 | METHODS OF TARGETED DRUG DEVELOPMENT | Errico, Joseph P. (US) | 2014-07-10 | — | — | US | disclosed |
| CN-102811723-A | Methods and compositions for targeted drug development | ERRICO JOSEPH P | 2012-12-05 | — | — | CN | disclosed |
| EP-2521553-A2 | METHODS AND COMPOSITIONS OF TARGETED DRUG DEVELOPMENT | Errico, Joseph P. (US) | 2012-11-14 | — | — | EP | disclosed |
| US-20110301193-A1 | METHODS AND COMPOSITIONS OF TARGETED DRUG DEVELOPMENT | Errico, Joseph P. (US) | 2011-12-08 | — | — | US | disclosed |
| US-20110301193-A1 | METHODS AND COMPOSITIONS OF TARGETED DRUG DEVELOPMENT | Errico, Joseph P. (US) | 2011-12-08 | — | — | US | disclosed |
| US-20110301193-A1 | METHODS AND COMPOSITIONS OF TARGETED DRUG DEVELOPMENT | Errico, Joseph P. (US) | 2011-12-08 | — | — | US | disclosed |
| WO-2011085126-A2 | METHODS AND COMPOSITIONS OF TARGETED DRUG DEVELOPMENT | ERRICO JOSEPH P | 2011-07-14 | — | — | WO | disclosed |
| WO-2011085126-A2 | METHODS AND COMPOSITIONS OF TARGETED DRUG DEVELOPMENT | ERRICO JOSEPH P | 2011-07-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110301193-A1 | METHODS AND COMPOSITIONS OF TARGETED DRUG DEVELOPMENT | EGFR, ERBB2, ERBB3 | PLAU 2526/4885DYRK1A 352/4885NOS1 4655/4885 |
| US-20140163069-A1 | COMPOSITIONS OF TARGETED DRUG DEVELOPMENT | EGFR, ERBB2, ERBB3 | PLAU 2854/4885DYRK1A 466/4885NOS1 4689/4885 |
| US-20140194439-A1 | METHODS OF TARGETED DRUG DEVELOPMENT | EGFR, ERBB2, ERBB4 | PLAU 2220/4885DYRK1A 247/4885NOS1 4707/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.